Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin
| Autor: | Toshiaki Saito, Hideaki Yahata, Hiroaki Kobayashi, Kenzo Sonoda, Kunihiro Sakai, Yousuke Ueoka, Mototsugu Shimokawa, Akimasa Ichinoe, Kiyoko Kato, Satohiro Masuda, Tatsuhiro Ohgami, Makoto Nishida, Shinji Ogawa, Yasuyuki Hasuo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
medicine.medical_specialty Paclitaxel Nausea Genital Neoplasms Female Vomiting medicine.medical_treatment Morpholines Gastroenterology Dexamethasone Carboplatin Drug Hypersensitivity 03 medical and health sciences chemistry.chemical_compound Young Adult 0302 clinical medicine Double-Blind Method Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Serotonin 5-HT3 Receptor Antagonists 030212 general & internal medicine Aprepitant Aged Chemotherapy business.industry Remission Induction Combination chemotherapy Hematology General Medicine Middle Aged Regimen Oncology chemistry 030220 oncology & carcinogenesis Anesthesia Antiemetics Surgery Drug Therapy Combination Female medicine.symptom business Chemotherapy-induced nausea and vomiting medicine.drug |
| Zdroj: | International journal of clinical oncology. 21(3) |
| ISSN: | 1437-7772 |
| Popis: | Substance P contributes to the hypersensitivity reaction (HSR) to paclitaxel in a rat model. Aprepitant acts as an inhibitor of the binding of substance P to the neurokinin-1 receptor and, consequently, may reduce the frequency of paclitaxel-induced HSR. While aprepitant has a prophylactic effect against vomiting caused by high-dose cisplatin, the benefits of aprepitant have not been clearly demonstrated in patients receiving paclitaxel and carboplatin (TC) combination chemotherapy. We conducted a multicenter, placebo-controlled, double-blind, randomized study in Japanese patients with gynecologic cancer who received TC combination chemotherapy. Patients received aprepitant or placebo together with both a 5-HT3 receptor antagonist and dexamethasone prior to chemotherapy. The primary endpoint was the proportion of patients with HSR, and the secondary endpoints were the proportion of patients with “no vomiting”, “no significant nausea”, and complete response, respectively. Of the 324 randomized patients, 297 (151 in the aprepitant group; 146 in the placebo group) were evaluated. The percentage of patients with HSR (9.2 vs. 7.5 %, respectively; P = 0.339) was not significantly different between the groups. The percentage of “no vomiting” patients (78.2 vs. 54.8 %; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink